Humana Inc. (NYSE:HUM) Shares Acquired by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its position in Humana Inc. (NYSE:HUM) by 59.0% during the 4th quarter, Holdings Channel reports. The fund owned 338,801 shares of the insurance provider’s stock after acquiring an additional 125,697 shares during the quarter. Russell Investments Group Ltd.’s holdings in Humana were worth $154,948,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in HUM. Exchange Traded Concepts LLC lifted its holdings in Humana by 103.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 2,883 shares of the insurance provider’s stock worth $1,403,000 after buying an additional 1,463 shares during the last quarter. UMB Bank n.a. grew its position in shares of Humana by 2.8% in the 3rd quarter. UMB Bank n.a. now owns 805 shares of the insurance provider’s stock valued at $392,000 after buying an additional 22 shares during the last quarter. Aaron Wealth Advisors LLC purchased a new stake in Humana in the third quarter valued at $213,000. Handelsbanken Fonder AB grew its holdings in shares of Humana by 1.3% during the third quarter. Handelsbanken Fonder AB now owns 42,188 shares of the insurance provider’s stock worth $20,525,000 after purchasing an additional 541 shares during the last quarter. Finally, MCF Advisors LLC lifted its holdings in shares of Humana by 22.8% in the 3rd quarter. MCF Advisors LLC now owns 3,869 shares of the insurance provider’s stock valued at $1,884,000 after purchasing an additional 718 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Down 1.8 %

NYSE HUM traded down $5.51 during trading hours on Friday, hitting $305.90. The company had a trading volume of 1,213,131 shares, compared to its average volume of 1,914,716. Humana Inc. has a fifty-two week low of $299.23 and a fifty-two week high of $541.21. The firm’s 50 day moving average is $327.77 and its 200 day moving average is $394.49. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.59. The company has a market capitalization of $36.86 billion, a price-to-earnings ratio of 19.05, a P/E/G ratio of 1.82 and a beta of 0.45.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company had revenue of $29.61 billion during the quarter, compared to the consensus estimate of $28.52 billion. During the same quarter last year, the company earned $9.38 earnings per share. Humana’s revenue for the quarter was up 10.7% on a year-over-year basis. Sell-side analysts anticipate that Humana Inc. will post 16.07 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.16%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s dividend payout ratio (DPR) is currently 22.04%.

Insider Transactions at Humana

In related news, Director Jorge S. Mesquita bought 545 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were acquired at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the purchase, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on HUM shares. Raymond James started coverage on Humana in a research report on Friday, March 22nd. They set a “market perform” rating on the stock. Argus downgraded Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, March 13th. Stephens lowered their target price on Humana from $550.00 to $430.00 and set an “overweight” rating on the stock in a report on Friday, January 26th. UBS Group lowered their price objective on shares of Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Humana from a “buy” rating to a “hold” rating and lowered their price target for the company from $595.00 to $360.00 in a research report on Thursday, January 25th. Eleven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $433.74.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.